Insmed Incorporated (NASDAQ: INSM) to Post 2021 Third Quarter Earnings of ($ 0.77) Per Share, SVB Leerink Forecast
Insmed Incorporated (NASDAQ: INSM) – SVB Leerink research analysts lowered their Q3 2021 EPS estimates for Insmed stocks in a research report released on Wednesday, September 22. SVB Leerink analyst J. Schwartz now expects the biopharmaceutical company to post earnings per share of ($ 0.77) for the quarter, down from its previous estimate of $ 0.74 . SVB Leerink also released Insmed earnings estimates for the fourth quarter of 2021 at ($ 0.76) EPS, earnings for fiscal 2021 at ($ 3.34) EPS, earnings Q1 2022 at ($ 0.79 ) EPS, Q2 2022 earnings at $ 0.77 EPS, Q3 2022 earnings at ($ 0.81 EPS), Fourth quarter 2022 earnings at ($ 0.82) EPS, FY2022 earnings at ($ 3.18) EPS and FY2023 earnings at ($ 2.85 EPS). Insmed (NASDAQ: INSM) last released its results on Thursday, August 5. The biopharmaceutical company reported ($ 1.07) earnings per share for the quarter, missing ($ 0.18) Thomson Reuters consensus estimate of ($ 0.89). The company posted revenue of $ 45.37 million in the quarter, compared to analysts’ estimates of $ 43.72 million. Insmed had a negative net margin of 219.67% and a negative return on equity of 105.70%. The company’s revenue increased 6.8% compared to the same quarter last year. During the same period last year, the company achieved EPS ($ 0.64).
Separately, Zacks investment research upgraded Insmed’s actions from a “sell” note to a “keep” note in a research note on Thursday, September 9. One research analyst rated the stock with a conservation rating and six gave the company a buy rating. Based on data from MarketBeat, Insmed has an average rating of “Buy” and a consensus price target of $ 50.57.
Insmed shares opened at $ 27.01 on Monday. The company has a market cap of $ 3.11 billion, a P / E ratio of -7.52 and a beta of 2.25. Insmed has a minimum of $ 22.00 over 52 weeks and a maximum of $ 45.44 over 52 weeks. The company has a quick ratio of 9.81, a current ratio of 10.42 and a debt ratio of 1.06. The company’s 50-day moving average is $ 25.82 and its two-hundred-day moving average is $ 28.84.
A number of institutional investors have recently increased or reduced their holdings in the INSM. Eaton Vance Management purchased a new stake in Insmed shares during the 1st quarter valued at approximately $ 36,000. Harbor Investment Advisory LLC purchased a new position in Insmed shares in the second quarter valued at $ 58,000. E Fund Management Co. Ltd. acquired a new stake in Insmed shares in the first quarter valued at $ 121,000. HighMark Wealth Management LLC raised its stake in Insmed shares by 675.7% during the second quarter. HighMark Wealth Management LLC now owns 5,019 shares of the biopharmaceutical company valued at $ 137,000 after purchasing an additional 4,372 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new equity stake in Insmed during the second quarter for a value of $ 147,000.
Insmed Company Profile
Insmed Incorporated is a global biopharmaceutical company with a mission to transform the lives of patients with severe and rare diseases. Insmed’s first commercial product is ARIKAYCE® (Amikacin Liposome Inhalation Suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a regimen Combined antibacterial for adult patients with little or no alternative treatment option.
Recommended Story: Why Are Fixes Happening?
This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Insmed now?
Before you consider Insmed, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and Insmed was not on the list.
Although Insmed currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here